SEC Comment Letter 0000000000-22-012329 to Context Therapeutics Inc. (CNTX) (CIK 0001842952) (CNTX)
Context Therapeutics Inc. (CNTX) (CIK 0001842952)
Date: Nov. 14, 2022 · CIK: 0001842952 · Accession: 0000000000-22-012329
AI Filing Summary & Sentiment
File numbers found in text: 333-268266
Letter
United States securities and exchange commission logo November 14, 2022 Martin Lehr Chief Executive Officer Context Therapeutics Inc. 2001 Market Street, Suite 3915, Unit #15 Philadelphia, Pennsylvania 19103 Re:Context Therapeutics Inc. Registration Statement on Form S-3 Filed November 9, 2022 File No. 333-268266 Dear Martin Lehr: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Walter Mostek, Esq.
Show Raw Text
United States securities and exchange commission logo
November 14, 2022
Martin Lehr
Chief Executive Officer
Context Therapeutics Inc.
2001 Market Street, Suite 3915, Unit #15
Philadelphia, Pennsylvania 19103
Re:Context Therapeutics Inc.
Registration Statement on Form S-3
Filed November 9, 2022
File No. 333-268266
Dear Martin Lehr:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Walter Mostek, Esq.